This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by BURCH, W. M. Articles by POSILLICO, J. T. Search for Related Content PubMed PubMed Citation Articles by BURCH, W. M. Articles by POSILLICO, J. T.

Hypoparathyroidism after I-131 Therapy with Subsequent Return of Parathyroid Function

Departments of Medicine and Surgery, Duke University Medical Center Durham, North Carolina 27710

Address correspondence and requests for reprints to: Warner Burch, M. D., Box 3283, Duke University Medical Center, Durham, North Carolina 27710.

A 22-year-old woman developed hypoparathyroidism in 1970, 10 months after treatment of hyperthyroidism with I-131. The hypocalcemia was corrected with Vitamin D₂ and oral calcium and she remained normocalcemic for 8 yr. In 1979 hypercalcemia was found and Vitamin D₂/calcium was discontinued. Because she remained normocalcemic without therapy for 3 yr, we measured the levels of immunoreactive and bioactive PTH in plasma stored since 1970 and in plasma obtained in 1982 to determine whether there had been restoration of parathyroid function. Indeed, PTH levels in 1970 while the patient was hypocalcemic were low. The bioactive PTH was 0.26 pg/ml (normal 1.5–30), whereas —COOH terminal immunoreactive PTH was 620 pg/ml (normal 600–1500) and midmolecule immunoreactive PTH was 433 pg/ml (normal 300– 900). In 1982 while normocalcemic the bioactive PTH and immunoreactive PTH were normal (5.18 pg/ml; —COOH, 970 pg/ml; midmolecule, 789 pg/ml, respectively). Thus, an unusual case of hypoparathyroidism after I-131 therapy with return of parathyroid function is documented by measurements of both immunoreactive and bioactive PTH.

Received January 24, 1983.

This article has been cited by other articles:

				S. A. Rivkees, C. Sklar, and M. Freemark The Management of Graves' Disease in Children, with Special Emphasis on Radioiodine Treatment J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3767 - 3776. [Full Text]

				G. D. GRAHAM and K. D. BURMAN Radioiodine Treatment of Graves' Disease: An Assessment of Its Potential Risks Ann Intern Med, December 1, 1986; 105(6): 900 - 905. [Abstract] [PDF]